A capsule containing fenretinide may someday be the cure for non-exudative macular degeneration. The most damaging form of dry macular degeneration is called geographic atrophy (GA). It is different from the “wet” form as there are no abnormal leaky blood vessels within the retina. Patients with geographic atrophy experience vision loss due to atrophy, or cell death, of the pigmented layer within the retina.
A small 2 year study has been underway and the 12 month results look promising. Patients were given fenretinide in one of two doses versus placebo.
It is believed that GA is a result of lipofuscin and serum retinol-binding protein (RBP) build up in the retinal pigment epithelium (the layer principally affected in the retina), that is, increased lipofuscin and RBP causes cell death of the RPE layer.
Patients receiving either dose of fenretinide were noted to have a slower rate of progression of the atrophic lesions. Also, while there was an inverse relationship between oral fenretinide and lower RBP, none was noted before the trial started. To state another way, it looks as if the oral fenretinide did indeed lower RBP. It then further implicates RBP to be involved in the chain of events leading to RPE cell death.
Lastly, it also appears that the smaller, and earlier, the lesion are treated, the better the response.
What does this mean? As I learn more and more about the cascade of events leading up to cell death of the RPE, it becomes clearer that we soon will be treating patients with dry/non-exudative ARMD. Especially exciting is the fact that treatment is a simple capsule versus and intraocular injection. The trial will be completed in 2010.
Link to the article.
Randall V. Wong, M.D.
Ophthalmologist, Retina Specialist
Fairfax, Virginia
***This post is for information purposes only. This posting does not offer legal or medical advice, so nothing in it should be construed as legal or medical advice. The information on this blog/post is only offered for informational purposes. You shouldn’t act or rely on anything in this blog or posting or use it as a substitute for legal/medical advice from a licensed professional. The content of this posting may quickly become outdated, especially due to the nature of the topics covered, which are constantly evolving. The materials and information on this posting/blog are not guaranteed to be correct, complete, or timely. Nothing in this posting/blog and nothing you or I do creates a doctor-patient relationship between you and the blog; between you and me; or between you and Randall Wong, M.D. or RetinaEyeDoctor.com. Even if you try to contact me through the blog or post a comment on the blog you are still not creating a doctor-patient relationship. Although, I am a doctor, I’m not YOUR doctor until and unless there is a written agreement specifically providing for a doctor-patient relationship.***
What is the status of fenretinide as of April 2011? Has the third phase of clinical trials started? When will the treatment be available to the public? Thank you.
Elizabeth,
Your guess is as good as mine. At the AAO meeting last fall, it was reported that Phase II clinical trials demonstrated a benefit by reducing the chance of transforming to wet ARMD by 50%.
I can not find anything during my short search tonight. My guess is that you couldn’t either. I’ll be on the lookout.
Thanks,
Randy